去纤苷推荐的使用量是多少？

Defibrotide is a very effective drug for preventing and treating hepatic veno-occlusive disease (HVOD) after hematopoietic stem cell transplantation (HSCT). It is also called defibrotide sodium and defiteli. It was developed by Jazz Company and was approved for marketing in the EU in October 2013. HVOD is one of the serious complications of HSCT. The mortality rate of patients with severe HVOD can be as high as 100%, and the risk of death is extremely high. Defibrotide is currently recognized as the most promising new drug for the treatment of HVOD.

In March 2016, defibrotide was approved for marketing in the United States and was also granted "orphan drug" status by the FDA. As a new drug, many patients are not clear about the usage and dosage of defibrotide. Let’s give a brief introduction to it.

Defibrotide is an injectable medication that can be used by both adults and children. The recommended dose of defibrotide (defiteli) is 6.25 mg/kg given as a 2-hour intravenous infusion every 6 hours based on body weight. The minimum duration of treatment with defibrotide is 21 days. If signs and symptoms of hepatic VOD have not resolved after 21 days, continue defibrotide until resolution of VOD or up to a maximum of 60 days.

As a prescription drug, the use of defibrotide needs to be carried out under the guidance of a professional doctor with treatment experience. It must be diluted before infusion. Do not use it if the patient is allergic to defibrotide (defiteli sodium) and its ingredients. Defibrotide should not be coadministered with other intravenous drugs simultaneously in the same intravenous line, and concomitant use of this drug with a systemic anticoagulant or fibrinolytic therapy may increase the risk of bleeding (excluding use for routine maintenance or central venous line reopening).

To ensure patient safety during treatment, patients should be monitored for signs of bleeding and defibrotide therapy should not be initiated if the patient has active bleeding. Special groups of people need to truthfully inform their doctor about their condition in advance when taking medication, and choose a treatment plan based on the doctor’s judgment.